Details of Drug

Details of Drug

 Drug General Information (ID: D1557)
  Drug Name
Testolactone
  Drug Type Small molecule
  Drug Synonymous
Fludestrin; Teolit; Teslac; Teslak; Testolacton; Testolactona; Testolactonum; Testolattone; Bristol Myers SquibbBrand of Testolactone; Testolattone [DCIT]; SQ 9538; Bristol-Myers Squibb Brand of Testolactone; DELTA1-Dehydrotestolactone; DELTA1-Dehydrotestololactone; DELTA1-Testololactone; SQ-9538; TESLAC (TN);Teslac (TN); Testolactona [INN-Spanish]; Testolactone [USAN:INN]; Testolactonum [INN-Latin]; Delta(1)-Dehydrotestolactone; Delta(1)-Testolactone; Delta(1)-Testololactone; Delta(1)-testololactone; Delta-1-testololactone; Testolactone (USP/INN); D-Homo-17A-oxaandrosta-1,4-diene-3,17-dione; D-homo-17a-oxaandrosta-1,4-diene-3,17-dione; (4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-3,4,4a,5,6,10a,10b,11,12,12a-decahydro-2H-naphtho[2,1-f]chromene-2,8(4bH)-dione; (4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-4,4a,4b,5,6,10b,11,12-octahydro-3H-naphtho[2,1-f]chromene-2,8-dione; 1 Dehydrotestolactone; 1,2,3,4,4a,4b,7,9,10,10a-Decahydro-2-hydroxy-2,4b-dimethyl-7-oxo-1-phenanthrenepropionic acid delta-lactone; 1,2-Dehydrotestololactone; 1,2-Didehydrotestololactone; 1,2-didehydrotestololactone; 1-Dehydrotestolactone; 1-Dehydrotestololactone; 1-dehydrotestololactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, .delta.-lactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone (8CI); 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, lactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13.alpha.-hydroxy-3-oxo-, .delta.-lactone; 13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid .delta.-lactone; 13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid delta-lactone; 13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid delta-lactone; 17a-Oxa-D-homoandrosta-1,4-diene-3,17-dione; 17alpha-Oxo-D-homo-1,4-androstadiene-3,17-dione; 2H-Phenanthro[2,1-b]pyran-2,8(4bH)-dione, 3,4,4a,5,6,10a,10b,11,12,12a-decahydro-10a,12a-dimethyl-, lactone; 3-oxo-13,17-secoandrosta-1,4-dieno-17,13alpha-lactone
    Click to Show/Hide
  Disease Class 2C60-2C6Y: Breast cancer
  Therapeutic Class Antineoplastics
  Structure Could Not Find 2D Structure
3D Structure 2D Structure
  Formula C19H24O3
  InChI 1S/C19H24O3/c1-18-9-7-13(20)11-12(18)3-4-14-15(18)8-10-19(2)16(14)5-6-17(21)22-19/h7,9,11,14-16H,3-6,8,10H2,1-2H3/t14-,15+,16+,18+,19+/m1/s1
  InChIKey BPEWUONYVDABNZ-DZBHQSCQSA-N
  Canonical SMILES CC12CCC3C(C1CCC(=O)O2)CCC4=CC(=O)C=CC34C
  External Link
Pubchem ID 13769
CAS Number 968-93-4
CHEBI ID 9460
TTD ID D0C7JF

Drug-Drug Interaction Network
  Sunburst Graph
AM004  Affected intra/extra-hepatic metabolism
AM006  Pharmacodynamic additive effects
AM007  Pharmacodynamic antagonistic effects
BM017  CYP450 enzyme inhibition
BM047  Additive thrombogenic effects
BM050  Increased risk of bleeding
BM083  Potentiated the pharmacological effects (Unspecific)
BM107  Attenuated pharmacological effects (Unspecific)
BM108  Increased risk of hypercalcemia
  Relation Graph
 Full list of drugs interacting with Testolactone
      Affected intra/extra-hepatic metabolism
   CYP450 enzyme inhibition Drug Num:  1
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0946
 
Lonafarnib
 
C27H31Br2ClN4O2
 
148195 
Moderate    Inter Info   
[16]
      Pharmacodynamic additive effects
   Additive thrombogenic effects Drug Num:  3
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0261
 
Carfilzomib
 
C40H57N5O7
 
11556711 
Major    Inter Info   
[1], [2], [3]
D0385
 
Conestat alfa
 
NA
 
NA
Moderate    Inter Info   
[12], [13], [14], [15]
D0762
 
Human C1-esterase inhibitor
 
NA
 
NA
Moderate    Inter Info   
[12], [14], [15]
   Increased risk of bleeding Drug Num:  1
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D1711
 
Warfarin
 
C19H16O4
 
54678486 
Moderate    Inter Info   
[17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32]
   Potentiated the pharmacological effects (Unspecific) Drug Num:  4
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0925
 
Levothyroxine
 
C15H11I4NO4
 
5819 
Moderate    Inter Info   
[9], [10], [11]
D0934
 
Liothyronine
 
C15H12I3NO4
 
5920 
Moderate    Inter Info   
[9], [10], [11]
D0935
 
Liotrix
 
C30H21I7N2Na2O8
 
71371 
Moderate    Inter Info   
[9], [10], [11]
D1577
 
Thyroid, porcine
 
NA
 
NA
Moderate    Inter Info   
[9], [10], [11]
   Increased risk of hypercalcemia Drug Num:  2
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D1754
 
Calcitriol (topical)
 
C27H44O3
 
5280453 
Moderate    Inter Info   
[4], [5]
D1753
 
Calcipotriol (topical)
 
C27H40O3
 
5288783 
Moderate    Inter Info   
[4], [5]
      Pharmacodynamic antagonistic effects
   Attenuated pharmacological effects (Unspecific) Drug Num:  10
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0387
 
Conjugated estrogens
 
C18H21NaO5S
 
45357473 
Moderate    Inter Info   
[6], [7], [8]
D0388
 
Conjugated estrogens (topical)
 
C18H21NaO5S
 
45357473 
Moderate    Inter Info   
[6], [7], [8]
D0606
 
Estradiol
 
C18H24O2
 
5757 
Moderate    Inter Info   
[6], [7], [8]
D0607
 
Estradiol (topical)
 
C18H24O2
 
5757 
Moderate    Inter Info   
[6], [7], [8]
D0605
 
Esterified estrogens
 
NA
 
NA
Moderate    Inter Info   
[6], [7], [8]
D0608
 
Estramustine
 
C23H31Cl2NO3
 
259331 
Moderate    Inter Info   
[6], [7], [8]
D0610
 
Estrone sulfate
 
C18H22O5S
 
3001028 
Moderate    Inter Info   
[6], [7], [8]
D0611
 
Estrone sulfate (topical)
 
C18H22O5S
 
3001028 
Moderate    Inter Info   
[6], [7], [8]
D0619
 
Ethinylestradiol
 
C20H24O2
 
5991 
Moderate    Inter Info   
[6], [7], [8]
D1011
 
Mestranol
 
C21H26O2
 
6291 
Moderate    Inter Info   
[6], [7], [8]
References
1 Cerner Multum, Inc. "Australian Product Information.".
2 Product Information. Kyprolis (carfilzomib). Onyx Pharmaceuticals Inc, South San Francisco, CA.
3 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
4 Product Information. Vectical (calcitriol topical). Galderma Laboratories Inc, Cranbury, NJ.
5 Product Information. Dovonex (calcipotriene). Westwood Squibb Pharmaceutical Corporation, Eatontown, NJ.
6 Product Information. Aromasin (exemestane) Pharmacia &amp Upjohn, Kalamazoo, MI.
7 Product Information. Femara (letrozole). Novartis Pharmaceuticals, East Hanover, NJ.
8 Product Information. Arimidex (anastrozole). Zeneca Pharmaceuticals, Wilmington, DE.
9 Product Information. Armour thyroid (thyroid desiccated). Forest Pharmaceuticals, St. Louis, MO.
10 Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67. [PMID: 19667002]
11 Arafah BM "Decreased levothyroxine requirement in women with hypothyroidism during androgen therapy for breast cancer." Ann Intern Med 121 (1994): 247-51
12 Product Information. Berinert (complement C1 esterase inhibitor). CSL Behring, King of Prussia, PA.
13 Product Information. Cinryze (complement C1 esterase inhibitor). ViroPharma Incorporated, Exton, PA.
14 Product Information. Ruconest (conestat alfa). Valeant Pharmaceuticals, Costa Mesa, CA.
15 Gandhi PK, Gentry WM, Bottorff MB "Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database." Pharmacotherapy 32 (2012): 902-9. [PMID: 23033229]
16 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
17 de Oya JC, del Rio A, Noya M, Villanueva A "Decreased anticoagulant tolerance with oxymetholone in paroxysmal nocturnal haemoglobinuria." Lancet 2 (1971): 259. [PMID: 4104789]
18 Edwards MS, Curtis JR "Decreased anticoagulant tolerance with oxymetholone." Lancet 2 (1971): 221. [PMID: 4104889]
19 Ekert H, Muntz RH, Colebatch JH "Decreased anticoagulant tolerance with oxymetholone." Lancet 2 (1971): 609-10. [PMID: 4106131]
20 Goulbourne IA, Macleod DA "An interaction between danazol and warfarin: case report." Br J Obstet Gynaecol 88 (1981): 950-1. [PMID: 7272269]
21 Husted S, Andreasen F, Foged L "Increased sensitivity to phenprocoumon during methyltestosterone therapy." Eur J Clin Pharmacol 10 (1976): 209-16.
22 Longridge RG, Gillam PM, Barton GM "Decreased anticoagulant tolerance with oxymetholone." Lancet 2 (1971): 90. [PMID: 4103994]
23 Lorentz SM, Weibert RT "Potentiation of warfarin anticoagulation by topical testosterone ointment." Clin Pharm 4 (1985): 333-5. [PMID: 4006400]
24 Meeks ML, Mahaffey KW, Katz MD "Danazol increases the anticoagulant effect of warfarin." Ann Pharmacother 26 (1992): 641-2. [PMID: 1591422]
25 Murakami M, Odake K, Matsuda T, Onchi K, Umeda T, Nishino T "Effects of anabolic steroids on anticoagulant requirements." Jpn Circ J 29 (1965): 243-50. [PMID: 14311825]
26 Product Information. Teslac (testolactone). Bristol-Myers Squibb, Princeton, NJ.
27 Middleton T, Turner L, Fennell C, et al. Complications of injectable testosterone undecanoate in routine clinical practice.?Eur J Endocrinol. 2015;172(5):511-517. [PMID: 25637074]
28 Robinson BH, Hawkins JB, Ellis JE, Moore-Robinson M "Decreased anticoagulant tolerance with oxymetholone." Lancet 1 (1971): 1356. [PMID: 4103421]
29 Schrogie JJ, Solomon HM "The anticoagulant response to bishydroxycoumarin. II. The effect of D-thyroxine, clofibrate, and norethandrolone." Clin Pharmacol Ther 8 (1967): 70-7. [PMID: 4163172]
30 Shaw PW, Smith AM "Possible interaction of warfarin and stanozolol." Clin Pharm 6 (1987): 500-2. [PMID: 3690998]
31 Small M, Peterkin M, Lower GD, et al "Danazol and oral anticoagulants." Scott Med J 27 (1982): 331-2. [PMID: 7146883]
32 Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83. [PMID: 7944078]